Topics:

Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)

Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)

VANCOUVER—Inex Pharmaceuticals Corporation has announced positive results from a pivotal phase II/III clinical trial evaluating its lead anticancer product Onco TCS (liposomal vincristine) as single-agent therapy for relapsed aggressive non-Hodgkin’s lymphoma. The trial results will form the basis for a New Drug Application seeking approval for marketing from the US Food and Drug Administration (FDA). The 102 study patients had received an average of four other regimens, and 75% had resistant disease. The overall response rate with Onco TCS was 24%, including five complete responses.

 
Loading comments...
Please Wait 20 seconds or click here to close